DARE Valuation

Dare Bioscience Inc

Add to Watchlist

Advanced Chart

1.960

+0.03(1.554%)1D

DARE Relative Valuation

DARE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, DARE is overvalued; if below, it's undervalued.

Historical Valuation

Dare Bioscience Inc (DARE) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.96 is considered Undervalued compared with the five-year average of -2.95. The fair price of Dare Bioscience Inc (DARE) is between 10.73 to 27.99 according to relative valuation methord. Compared to the current price of 1.96 USD , Dare Bioscience Inc is Undervalued By 81.74%.

Relative Value

Fair Zone

10.73-27.99

Current Price：1.96

81.74%

Undervalued

-1.14

Trailing

Forward

0.00

EV/EBITDA

Dare Bioscience Inc. (DARE) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

-0.97

EV/EBIT

Dare Bioscience Inc. (DARE) has a current EV/EBIT of -0.97. The 5-year average EV/EBIT is -1.59. The thresholds are as follows: Strongly Undervalued below -2.82, Undervalued between -2.82 and -2.21, Fairly Valued between -0.98 and -2.21, Overvalued between -0.98 and -0.37, and Strongly Overvalued above -0.37. The current Forward EV/EBIT of -0.97 falls within the Overvalued range.

1.96

Dare Bioscience Inc. (DARE) has a current PS of 1.96. The 5-year average PS is 17.70. The thresholds are as follows: Strongly Undervalued below -21.03, Undervalued between -21.03 and -1.66, Fairly Valued between 37.07 and -1.66, Overvalued between 37.07 and 56.43, and Strongly Overvalued above 56.43. The current Forward PS of 1.96 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

Dare Bioscience Inc. (DARE) has a current P/OCF of 0.00. The 5-year average P/OCF is -0.15. The thresholds are as follows: Strongly Undervalued below -3.59, Undervalued between -3.59 and -1.87, Fairly Valued between 1.57 and -1.87, Overvalued between 1.57 and 3.29, and Strongly Overvalued above 3.29. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Dare Bioscience Inc. (DARE) has a current P/FCF of 0.00. The 5-year average P/FCF is -0.11. The thresholds are as follows: Strongly Undervalued below -3.78, Undervalued between -3.78 and -1.94, Fairly Valued between 1.72 and -1.94, Overvalued between 1.72 and 3.55, and Strongly Overvalued above 3.55. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

Dare Bioscience Inc (DARE) has a current Price-to-Book (P/B) ratio of -1.39. Compared to its 3-year average P/B ratio of -3.36 , the current P/B ratio is approximately -58.63% higher. Relative to its 5-year average P/B ratio of -4.13, the current P/B ratio is about -66.37% higher. Dare Bioscience Inc (DARE) has a Forward Free Cash Flow (FCF) yield of approximately -45.95%. Compared to its 3-year average FCF yield of -42.72%, the current FCF yield is approximately 7.57% lower. Relative to its 5-year average FCF yield of -38.27% , the current FCF yield is about 20.07% lower.

-1.39

P/B

Median3y

-3.36

Median5y

-4.13

-45.95

FCF Yield

Median3y

-42.72

Median5y

-38.27

Competitors Valuation Multiple

The average P/S ratio for DARE's competitors is 2.17, providing a benchmark for relative valuation. Dare Bioscience Inc Corp (DARE) exhibits a P/S ratio of 1.96, which is -9.82% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Neurosense Therapeutics Ltd

NanoViricides Inc (Pre-Reincorporation)

1.66

28.94M

CASI.O

CASI Pharmaceuticals Inc

Performance Decomposition

Market capitalization of DARE increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of DARE in the past 1 year is driven by Unknown.